Cargando…

Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review

PURPOSE: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhry, Jonathan S., Pena, M. Juliana, Pomputius, Ariel, Giap, Fantine, Vega, Raymond B. Mailhot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563665/
https://www.ncbi.nlm.nih.gov/pubmed/37823018
http://dx.doi.org/10.14338/IJPT-22-00042.1
_version_ 1785118382234796032
author Fakhry, Jonathan S.
Pena, M. Juliana
Pomputius, Ariel
Giap, Fantine
Vega, Raymond B. Mailhot
author_facet Fakhry, Jonathan S.
Pena, M. Juliana
Pomputius, Ariel
Giap, Fantine
Vega, Raymond B. Mailhot
author_sort Fakhry, Jonathan S.
collection PubMed
description PURPOSE: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinical trials involving proton therapy in the United States. MATERIALS AND METHODS: Published manuscripts were identified in PubMed, Embase, World of Science, and Cochrane. Phase 2 trials evaluating proton therapy for US patients were included. For each article in the study, data were collected comprising authors, title, and publication year, and clinical trial numbers were verified. Additional data included tumor site, primary institution, sample size, reported race/ethnicity, and raw number/percentile of race/ethnicity. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. RESULTS: Overall, 970 titles were identified; 636 remained after duplicate screening, and 75 full-text articles were assessed. We identified 38 eligible manuscripts for inclusion comprising 2648 patients. Only 15 (39%) of the publications reported race/ethnicity. Of these, 8 (21%) and 10 (26%) documented Hispanic or Black trial participants, respectively; however, only 6 (16%) documented trial participation for both Hispanic and Black patients. Of the 1409 patients with a documented race/ethnicity, 89.0% (n = 1254) were non-Hispanic white, 5.3% (n = 75) were Black, and 2.2% (n = 31) were Hispanic. Other and unknown race/ethnicity comprised the remaining patients (3.5%; n = 49). CONCLUSION: We identified underreporting of demographic data in published phase 2 proton therapy trials, which unfortunately mirrored underreporting for cancer drug clinical trials. We also noted dramatic Black and Hispanic patient underrepresentation across the trials in which race and ethnicity are reported. Findings highlight the urgent need to identify and address barriers to proton therapy trials for Black and Hispanic patients ensuring clinical trials in radiation oncology are representative of the patients seen in clinical practice.
format Online
Article
Text
id pubmed-10563665
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Particle Therapy Co-operative Group
record_format MEDLINE/PubMed
spelling pubmed-105636652023-10-11 Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review Fakhry, Jonathan S. Pena, M. Juliana Pomputius, Ariel Giap, Fantine Vega, Raymond B. Mailhot Int J Part Ther Review PURPOSE: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinical trials involving proton therapy in the United States. MATERIALS AND METHODS: Published manuscripts were identified in PubMed, Embase, World of Science, and Cochrane. Phase 2 trials evaluating proton therapy for US patients were included. For each article in the study, data were collected comprising authors, title, and publication year, and clinical trial numbers were verified. Additional data included tumor site, primary institution, sample size, reported race/ethnicity, and raw number/percentile of race/ethnicity. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. RESULTS: Overall, 970 titles were identified; 636 remained after duplicate screening, and 75 full-text articles were assessed. We identified 38 eligible manuscripts for inclusion comprising 2648 patients. Only 15 (39%) of the publications reported race/ethnicity. Of these, 8 (21%) and 10 (26%) documented Hispanic or Black trial participants, respectively; however, only 6 (16%) documented trial participation for both Hispanic and Black patients. Of the 1409 patients with a documented race/ethnicity, 89.0% (n = 1254) were non-Hispanic white, 5.3% (n = 75) were Black, and 2.2% (n = 31) were Hispanic. Other and unknown race/ethnicity comprised the remaining patients (3.5%; n = 49). CONCLUSION: We identified underreporting of demographic data in published phase 2 proton therapy trials, which unfortunately mirrored underreporting for cancer drug clinical trials. We also noted dramatic Black and Hispanic patient underrepresentation across the trials in which race and ethnicity are reported. Findings highlight the urgent need to identify and address barriers to proton therapy trials for Black and Hispanic patients ensuring clinical trials in radiation oncology are representative of the patients seen in clinical practice. The Particle Therapy Co-operative Group 2023-05-15 /pmc/articles/PMC10563665/ /pubmed/37823018 http://dx.doi.org/10.14338/IJPT-22-00042.1 Text en ©Copyright 2023 The Author(s) https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed in accordance with Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ).
spellingShingle Review
Fakhry, Jonathan S.
Pena, M. Juliana
Pomputius, Ariel
Giap, Fantine
Vega, Raymond B. Mailhot
Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title_full Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title_fullStr Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title_full_unstemmed Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title_short Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
title_sort racial and ethnic demographic reporting in phase 2 proton therapy clinical trials: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563665/
https://www.ncbi.nlm.nih.gov/pubmed/37823018
http://dx.doi.org/10.14338/IJPT-22-00042.1
work_keys_str_mv AT fakhryjonathans racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview
AT penamjuliana racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview
AT pomputiusariel racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview
AT giapfantine racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview
AT vegaraymondbmailhot racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview